Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
ContributorsTempleton, Arnoud J; Dutoit Vallotton, Valérie; Cathomas, Richard; Rothermundt, Christian; Bärtschi, Daniela; Dröge, Cornelia; Gautschi, Oliver; Borner, Markus; Fechter, Eva; Stenner, Frank; Winterhalder, Ralph; Müller, Beat; Schiess, Ralph; Wild, Peter J; Rüschoff, Jan H; Thalmann, George; Dietrich, Pierre-Yves; Aebersold, Ruedi; Klingbiel, Dirk; Gillessen, Silke
Published inEuropean urology, vol. 64, no. 1, p. 150-158
Publication date2013
Abstract
Affiliation
Research group
Citation (ISO format)
TEMPLETON, Arnoud J et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). In: European urology, 2013, vol. 64, n° 1, p. 150–158. doi: 10.1016/j.eururo.2013.03.040
Main files (1)
Article (Published version)
Identifiers
- PID : unige:33771
- DOI : 10.1016/j.eururo.2013.03.040
- PMID : 23582881
ISSN of the journal0302-2838
